Established anti-CMV therapeutics

Valaciclovir
To date, the only established CMV antiviral to undergo investigations during pregnancy is valaciclovir, the prodrug of the nucleoside While all the various studies on using HIG to prevent or treat congenital CMV to date have shown a beneficial trend, the lack of data from properly designed randomised clinical trials limits the conclusions that can be drawn and prevents recommendation as a 
Novel therapies with clinical drug candidates
Brincidofovir Brincidofovir (or CMX001) is an alkoxyalkyl ester analogue of cidofovir (a nucleoside analogue of cytosine), which acts by competitive inhibition of cysteine incorporation into the viral DNA strand and thus causing premature chain termination. While no data are available for the safety and efficacy of brincidofovir to prevent or treat congenital CMV, several studies in animal guineapig models show cidofovir and brincidofovir have potential benefits in preventing CMV transmission during pregnancy [6] [7] [8] . A recent phase II study on the efficacy of brincidofovir to prevent CMV disease in haematopoietic-cell transplant (HSCT) recipients showed promising results 9 . Patients who received brincidofovir twice weekly had significantly fewer incidence of CMV events than those who received placebo (10% v. 37%; P = 0.002). Brincidofovir has now entered phase III trials in HSCT recipients. CDK7 inhibitor with broad anti-herpesviral activity and low cytotoxicity profiles nicely substantiates this concept 37 and now awaits proof-of-concept investigations in animal models. Thus, the kinase inhibitor strategy may lead to a novel option for antiviral therapy approaches that already proved to be highly potent in current anticancer therapy.
Inhibitors of viral nuclear egress
In vivo, HCMV production is largely co-regulated by the interaction between viral and cellular proteins and by the formation of virushost multi-protein complexes. Recently, the viral 'nuclear egress complex' (NEC) has attracted the deep interest of researchers, since it represents a regulatory key position of viral replication and a Figure 2 . The postulated cytomegalovirus nuclear egress complex (NEC) and potential novel therapeutic targets. Recruitment of viral and cellular components leads to phosphorylation (P) and partial disassembly of the nuclear lamina, allowing viral capsids to be packaged and exported to the cytoplasm through the nuclear envelope. Potential therapeutic targets include: (1) blocking formation and/or expression of the core viral NEC components pUL50 and pUL53; (2) preventing subsequent recruitment of viral/cellular components of the NEC; and (3) inhibiting NEC phosphorylation and subsequent disassembly of the nuclear lamina.
In Focus putative target for novel antiviral strategies 16, [38] [39] [40] [41] . During the nuclear phase of HCMV replication, viral capsids are packaged and exported to the cytoplasm by transition through the nuclear envelope (nuclear egress) for further virion maturation. Nuclear egress is a multi-step regulatory process that involves a phosphorylationtriggered distortion of the nuclear lamina [42] [43] [44] [45] . Pivotal for nuclear egress is the role of the two viral nuclear egress proteins pUL50 and pUL53 that heterodimerise and form a core for the multimeric viralcellular NEC 46 ( Figure 2 ). For antiviral strategies directed to the NEC as a novel target, two concepts are favoured at present, either (1) 
Conclusion
In the absence of a CMV vaccine or an evidence-based therapeutic option available to clinicians to prevent or treat fetal CMV infection during pregnancy, further scientific data is urgently needed on the safety and efficacy profiles of experimental and novel antiviral compounds. These investigations are extremely problematic given potential drug toxicities and the fact that CMV tropism and placental physiology are both highly host-specific. We have therefore begun investigating these experimental compounds in our established ex vivo placental explant model systems 47 
